Angiotensin II type I receptor blocker, Losartan, inhibits fibrosis in liver by suppressing TGF-beta1 production

@inproceedings{Ogata2016AngiotensinIT,
  title={Angiotensin II type I receptor blocker, Losartan, inhibits fibrosis in liver by suppressing TGF-beta1 production},
  author={Hisanobu Ogata and Hideko Noguchi and Toshio Ohtsubo and Jiyuan Liao and Hiroshi Kohara and Kazunari Yamada and Mutsunori Murahashi and Yasuki Hijikata and Atsushi Suetsugu and Robert M Hoffman and Kenzaburo Tani},
  year={2016}
}
Renin-angiotensin system is involved in liver fibrogenesis through activating hepatic stellate cells (HSCs). Losartan, which is an angiotensin II type 1 receptor antagonist, could function as a selective peroxisome proliferator-activated receptor c activator. Here we studied the effect of losartan on liver fibrosis in vivo. In vivo study, we used the Concanavalin A (Con A)-induced mouse liver fibrosis model through T cell activation and upregulation of TGF-β1. The mice were administrated ConA… CONTINUE READING
1 Citations
29 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 29 references

1919-1929

  • T Dejima, K Tamura, H Wakui, A Maeda, M Ohsawa, 29 et al. Prepubertal angiotensin blockade exerts lon Hypertens
  • A B Cont Los * 0 Control Losartan TG F 1 s…
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…